A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan

References

• Hamborsky J, Kroger A, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Washington, DC: Public Health Foundation, Centers for Disease Control and Prevention (CDC); 2015
   Google Scholar
• Ludwig E, Bonanni P, Rohde G, et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012;21:57-65
   PubMedGoogle Scholar
• World Health Organization. 23-valent pneumococcal polysaccharide vaccine: WHO position paper. Weekly Epidemiological Record 2008;83:373-84
   PubMedGoogle Scholar
• Standing Committee on Vaccination at the Robert Koch Institute (STIKO). Scientific justification for the update of the pneumococcal vaccination recommendation for senior citizens. Epidemiol Bull 2016;36:351-86
   Google Scholar
• Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012;25:409-19
   PubMed Web of Science ®Google Scholar
• Kansenshouhou ni motoduku ishi oyobi juuishi no todokede ni tsuite - 11 Shinshusei haienkyuukin kansenshou [Notifiable diseases surveillance by doctors and veterinarians under the Infectious Disease Conrol Law]. Ministry of Health Labour and Welfare. Tokyo, Japan. 2013. Available at: http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-09-01.html
   Google Scholar
• Sunagawa F, Shinbashi R, Fukuzumi M, et al. 2013–2016-nen do no kansen-shō hassei dōkō chōsa ni okeru shinshū seihaien kyūkin kansen-shō no kaiseki [An analysis of invasive pneumococcal diseases in the infectious disease trend survey between 2013 and 2016]. Tokyo, Japan: National Institute of Infectious Diseases; 2016. Available at: http://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum = 201617010A
   Google Scholar
• Ohkusa Y, Sunagawa F, Takahashi M. 2013 ∼ 2015-Nendo no shinshū seihaien kyūkin infuruenza kin kansen-shō no kansen-shō hassei dōkō chōsa no kaiseki [An analysis of invasive pneumococcal and Haemophilus influenzae diseases in the infectious disease trend survey between 2013 and 2015]. Tokyo, Japan: National Institute of Infectious Diseases; 2016. Available at: http://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201517004A
   Google Scholar
• Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLOS One 2015;10:e0122247
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases (NIID). Haienkyukin kansen shou 2013 nen 3 gatsu genzai [S.Pneumococcus infectious diseases as of March, 2013]. IASR 2013;34:55-6
   Google Scholar
• Haien kyukin kansen-sho (Kourei-sya) [S.Pneumococcus infectious diseases (elderly population)]. Tokyo, Japan: Ministry of Health Labour and Welfare; 2014. Available at: http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/haienkyukin/index_1.html
   Google Scholar
• Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010;340:c1004
   PubMed Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis 2017;17:313-21
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-31
   PubMed Web of Science ®Google Scholar
• Pneumococcal polysaccharide vaccine (for adults) working team report. Tokyo, Japan: Ministry of Health Labour and Welfare; 2011. Available at: http://www.mhlw.go.jp/stf/shingi/2r98520000014wdd-att/2r98520000016rq9.pdf
   Google Scholar
• Oishi K, Ohshima N. Haienkyukin saisessyu no gaidansu (kaitei-ban). [Pneumococcal vaccine revaccination guidance - Revised]. J Jap Assoc Infect Dis 2017;91:543-52
   Google Scholar
• Teiki no yobousesshu Jisshishasu [Vaccination rate in NIP]. Tokyo, Japan: Ministry of Health Labour and Welfare. 2017. Available at: http://www.mhlw.go.jp/topics/bcg/other/5.html
   Google Scholar
• Yobou sesshu kihon keikaku [Basic policy for immunization program]. Tokyo, Japan: Ministry of Health Labour and Welfare; 2014. Available at: http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/kihonteki_keikaku/index.html
   Google Scholar
• Jiang Y, Gauthier A, Van der Linden M, et al. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev Pharmacoecon Outcomes Res 2012;12:645-60
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gauthier A, Keeping S, et al. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014;14:913-27
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dasbach EJ, Petigara T, et al., editors. 123 Vacunación en adultos mayores contra neumococo en Argentina. Análisis de costo-efectividad de inmunización con vacuna polisacárida neumocócica 23-valente (VPN) en comparación con vacuna conjugada neumocócica 13-valente (VCN13), no vacunación (NoVac) o vacunación con esquema secuencial (VCN13-VPN23). Congreso de la Sociedad Argentina de Infectología (SADI) XVI Congreso; May 22–24, 2016; Mendoza, Argentina.
   Google Scholar
• Jiang Y, Dasbach EJ, Yang HK, editors. A cost-effectiveness analysis of vaccinating the elderly with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to the 13-valent pneumococcal conjugate vaccine (PCV13) or no vaccination (NoVac) in Japan. International Interscience Conference of Infection and Chemotherapy (ICIC); November 2015; Korea.
   Google Scholar
• Jiang Y, Yang X, Petigara T, et al., editors. A cost-effectiveness analysis of vaccinating the elderly with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Brazil. ISPOR 6th Latin America Congress; September 17, 2017; São Paulo, Brazil.
   Google Scholar
• Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:189-209
   PubMed Web of Science ®Google Scholar
• Prato R, Tafuri S, Fortunato F, et al. Why it is still important that countries know the burden of pneumococcal disease. Hum Vaccines 2010;6:918-21
   PubMed Web of Science ®Google Scholar
• Fedson DS. Pneumococcal vaccination for older adults. Drug Aging 1999;15:21-30
   PubMed Web of Science ®Google Scholar
• Nenrei (kaku-sai), danjo betsu jinkō oyobi jinkōseihi - sō jinkō, nihonjin jinkō (Heisei 27-nen 10 gatsu 1-nichi genzai. [Population and sex ratio by single year of age and by sex – total Japanese population (1 October 2015)]. Statistics Bureau Ministry of Internal Affairs and Communications. Available at: http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103&listID=000001163203&disp=Other&requestSender=dsearch
   Google Scholar
• Nihon no shōrai suikei jinkō (Heisei 24-nen 1 gatsu suikei). Shussei chūi (shibō chūi) suikei (2011 ∼ 2060-nen) [Japanese population projection (January 2012 base). Medium birth/death rate scenario (2011–2016)]. Tokyo, Japan: National Institute of Population and Social Security Research; 2016. Available at: http://www.ipss.go.jp/syoushika/tohkei/newest04/sh2401smm.html
   Google Scholar
• Fukuzumi S, Nishi J, Maruyama T, et al. Seijin no shinshū seihaien kyūkin kansen-shō (IPD) no rinshō-zō to gen'in kin kessei-gata bunpu ni kansuru ekigaku (2013-nen 4 gatsu ∼2016-nen 3 gatsu). [An epidemiology study of clinical characteristics and serotype distribution of invasive pneumococcal diseases (IPD) in adults (April 2013 to March 2016)]. Tokyo, Japan: National Institute of Infectious Diseases; 2017. Available at: http://mhlw-grants.niph.go.jp/niph/search/NIDD02.do?resrchNum=201617010A
   Google Scholar
• Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect 2010;61:114-24
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham D, et al. Vaccines for preventing pneumococcal infection in adults (Review). Cochrane Database Syst Rev; 2013;1:CD000422
   PubMed Web of Science ®Google Scholar
• Grabenstein J, Manoff S. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012;30:4435-44
   PubMed Web of Science ®Google Scholar
• Fujikawa A, Suzue T, Jitsunari F. Evaluation of health-related quality of life using EQ-5D in Takamatsu, Japan. Environ Health Prev Med 2011;15:25-35
   Google Scholar
• Sisk JE, Whang W, Butler JC. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138:960-8
   PubMed Web of Science ®Google Scholar
• De Wals P, Petit G, Erickson LJ. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 2003;21:3757-64
   PubMed Web of Science ®Google Scholar
• des Portes V. Long-term follow-up of bacterial meningitis - sequels in children and adults: incidence, type, and assessment issues. Med Mal Infect 2009;39:572-80
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S. Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health 2017;20:372-8
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation: Oxford: Oxford University Press; 2011
   Google Scholar
• Kawakami K, Kishino H, Kanazu S, et al. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine 2016;34:3875-81
   PubMed Web of Science ®Google Scholar
• Erickson P, Wilson R, Shannon II. Years of healthy life. Healthy People 2000. Stat Notes 1995;7:1-15
   Google Scholar
• Torrance GW. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med 1982;20:37-45
   PubMedGoogle Scholar
• Shiyou yakuzai no yakka (yakka kijun) no ichibu wo kaisei suru ken (kokuji) heisei 28 nen kouseiroudou syou kokuji dai 55 gou. [Official gazette to notify drugs prices revised in the 2016 price revision.] Tokyo, Japan: Ministry of Health Labour and Welfare; 2016. Available at: http://www.mhlw.go.jp/file.jsp?id = 335774&name=file/06-Seisakujouhou-12400000-Hokenkyoku/0000114830.pdf
   Google Scholar
• Shinryou hosyu no sanntei houhou no ichibu wo kaisei suru ken (kokuji) heisei 28 nen kouseiroudou syou kokuji dai 52 gou. [Official gazette to notify treatment fees revised in the 2016 price revision.] Tokyo, Japan: Ministry of Health Labour and Welfare; 2016. Available at: http://www.mhlw.go.jp/file.jsp?id=335755&name=file/06-Seisakujouhou-12400000-Hokenkyoku/0000114811.pdf; http://www.mhlw.go.jp/file.jsp?id=335762&name=file/06-Seisakujouhou-12400000-Hokenkyoku/0000114818.pdf
   Google Scholar
• Shindan-gun bunrui betsu zaiin nissū (Heisei 27-nendo). [Length of stay by Diagnosis Procedure Combination (2016).] Tokyo, Japan: Tokyo, Japan Ministry of Health Labour and Welfare. 2016; Available at: http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000150717.xls
   Google Scholar
• Shindan-gun bunrui (DPC) denshi tensuu hyou (Heisei 27-nen 5 gatsu 20 nichi kousin) [Diagnosis Procedure Combination (DPC) points table (2017/05/20 updated)]. Ministry of Health Labour and Welfare. Available at: http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000039920.html
   Google Scholar
• Mikoshiba M, Shimizu M. A study of inpatients with community-acquired pneumonia after pneumococcal vaccination. J Jpn Soc Hosp Pharm 2011;47:1421-4
   Google Scholar
• Heisei 28-nendo shinryō hōshū kaitei no kihon hōshin (kosshi-an) ni kansuru sankō shiryō. [Reference materials on the basic policy of medical fee revision in 2016 (draft proposal).] Tokyo, Japan: Ministry of Health Labour and Welfare; 2015. Available at: http://www.mhlw.go.jp/file/05-Shingikai-12601000-Seisakutoukatsukan-Sanjikanshitsu_Shakaihoshoutantou/0000104924.pdf
   Google Scholar
• Watanabe A, Inoue S, Ohno T. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine for adult pneumococcal disease. Kokyūki naika [Resp Med] 2014;25:387-96
   Google Scholar
• Syogai kiso nenkin no jyukyuu youken shikyu kaishi jiki keisan houhou [Basic disability pension: qualifying conditions, payment start time and calculation]. Tokyo, Japan: Japan Pension Service; 2014. Available at: http://www.nenkin.go.jp/service/jukyu/shougainenkin/jukyu-yoken/20150514.html
   Google Scholar
• Heisei 26-nen shakaiiryō shinryō kōi-betsu chōsa - gekan - ika shinryō. Dai26-hyō [2014 Social Care Intervention Survey]. Tokyo, Japan: Statistics Bureau Ministry of Internal Affairs and Communications; 2015. Available at: http://www.e-stat.go.jp/SG1/estat/List.do?lid=000001186905
   Google Scholar